• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Genetics Market
    Genetics News
    Genetics Stocks
    • Genetics Market
    • Genetics News
    • Genetics Stocks

    ImmunoPrecise to Acquire U-Protein

    Bryan Mc Govern
    Jul. 04, 2017 09:19AM PST
    Genetics Investing

    ImmunoPrecise Antibodies signed a binding letter of intent with U-Protein Express BV to acquire all issued and outstanding shares of U-Protein.

    ImmunoPrecise Antibodies (TSXV:IPA) signed a binding letter of intent with U-Protein Express BV to acquire all issued and outstanding shares of U-Protein.
    As quoted in the press release:

    The key benefits of the acquisition of U-Protein by the Company are: (i) access to the European marketplace, (ii) materially accretive to the Company’s revenue, (iii) additional portfolio of services that are complementary to the Company, and (iv) diversifies and increases service offerings of the Company.
    U-Protein
    U-Protein is a privately held company based in Utrecht, The Netherlands and holds the rights to proprietary expression technology used in antibody production.  U-Protein is a Contract Research Organization (“CRO“) that offers fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications.  During the fiscal year ended December 31, 2016, U-Protein had revenues of €1,675,354 (CAD $2,479,524) and net income of €933,749 (CAD $1,381,948) (after tax and includes extraordinary income of €290,000 (CAD $429,200)).
    Terms of Transaction with U-Protein
    Under the binding letter of intent, the Company and U-Protein have agreed to negotiate a definitive agreement (the “Definitive Agreement“) whereby the Company will acquire all of the issued and outstanding shares of U-Protein for €6,830,000 (CAD$10,108,400) (the “Purchase Price“), of which (A) €2,734,732 (CAD$4,047,403) will be paid in cash on closing, (B) €2,047,634 (CAD$3,030,498) will be satisfied by the issuance of approximately 3,030,498 common shares of the Company on closing, and (C) €2,047,634 (CAD$3,030,498) in deferred payments over a three year period (the “Deferred Payments“).  The Deferred Payments may be made, at the election of the U-Protein shareholder, in cash or by the issuance of up to 3,030,498 common shares over a three-year period.  The Purchase price will be paid and/or issued to each shareholder of U-Protein in proportion to their respective shareholding of U-Protein.

    Click here to read the full press release.

    Source: www.newswire.ca

    immunoprecise antibodiescontract research organization
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Genetics Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×